Search | Clinical Trials Finder

Conditions: Schizophrenia
Interventions: quetiapine fumarate vs risperidone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 64
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 61 more

Conditions: Schizophrenia
Interventions: Galantamine, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Schizophrenia
Interventions: Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc); Drug
Lead sponsor: Matt Byerly; Other
Eligibility: 18 Years to 60 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Schizophrenia
Interventions: paliperidone, risperidone, haloperidole, perphenazine, aripiprazole, quetiapine, paliperidone palmitate, olanzapine; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 55
States / cities: Bullhead City, Arizona • Tuscon, Arizona • Little Rock, Arkansas + 52 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania

Conditions: Schizophrenia
Interventions: ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 27
States / cities: Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more

Conditions: Obesity
Interventions: Placebo, IHBG-10; Other · Dietary Supplement
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Stroke
Interventions: Haloperidol, Typical Antipsychotics, Atypical Antipsychotics; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,234,412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Schizophrenia and Schizoaffective Disorder
Interventions: Aripiprazole, Olanzapine, Risperidone, Quetiapine, Ziprasidone; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 63
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 54 more

Conditions: Dyskinesia, Drug-Induced
Interventions: Quetiapine, Risperidone, Olanzapine; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: San Diego, California

Conditions: Bipolar Disorder
Interventions: Ketogenic foodstuffs, Standard of Care Oral antipsychotics, Standard of care long acting injectable medication for bipolar disorder; Dietary Supplement · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Montgomery, Alabama

Conditions: Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
Interventions: risperidone, olanzapine, quetiapine, ziprasidone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 2
States / cities: St Louis, Missouri

Conditions: Antipsychotic-induced Weight Gain (AIWG)
Interventions: Miricorilant, Placebo; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 27
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 23 more

Conditions: Schizophrenia
Interventions: Risperidone, Olanzapine, Quetiapine; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 21 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: San Diego, California

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Quetiapine or Risperidone + Aripiprazole, Quetiapine or Risperidone + placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 48
States / cities: Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 37 more

Conditions: Antipsychotics, Pregnancy
Interventions: Antipsychotics, Non-antipsychotic medication, No Medication; Drug · Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Bipolar Disorder
Interventions: Lithium, Olanzapine, Divalproex, Risperidone, Quetiapine, Ziprasidone, Aripriprazole; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 10 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: quetiapine fumarate, risperidone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,098 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 63
States / cities: Little Rock, Arkansas • Mabelvale, Arkansas • Morrilton, Arkansas + 60 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Risperidone microspheres, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 8
States / cities: Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more

Conditions: Schizophrenia
Interventions: LY2140023, Olanzapine, Aripiprazole, Risperidone, Quetiapine; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 42
States / cities: Little Rock, Arkansas • Escondido, California • Garden Grove, California + 39 more

Conditions: Schizophrenia
Interventions: LY2140023, Placebo, Standard of Care; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more

Conditions: Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions: Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 6
States / cities: Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more

Conditions: Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
Interventions: quetiapine, olanzapine, risperidone; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 12 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Schizophrenia
Interventions: AVE1625, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 873 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Search by objective public record fields.

A Comparison of Seroquel vs. Risperidone in Schizophrenia

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Anti-psychotic Medication (Stable Dose) Weight Loss Study

A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

Movement Disorders Caused by Antipsychotic Drugs in Older Patients

Evaluating the Impact of Ketogenic Therapy on Symptom Severity and Metabolic Side Effect Profile Among Individuals Living With Bipolar Disorder in A Rural Southern Catchment Area

Glucose and Lipid Metabolism on Antipsychotic Medication

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

Antipsychotic Response in Schizophrenia

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

Maternal And Infant Antipsychotic Study

Treatment and Outcome of Early Onset Bipolar Disorder

A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

A Long-Term, Open-Label, Study on Schizophrenia

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

A Comparative Study of New Medications for Psychosis in Adolescents

Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia